Metabolic intervention continues its evolution with new data emerging from Eli Lilly’s Phase 3 TRIUMPH-4 study.  This investigation into Retatrutide, an investigational triple hormone receptor agonist, has produced outcomes that may fundamentally reshape expectations around peptide-based metabolic support. For those navigating the complex intersection of body weight and joint health, these findings offer meaningful insight